Piracetam 700mg - 50 capsules

Piracetam is a chemical compound that belongs to the racetam family and is widely recognized as the first nootropic. It was first synthesized in 1964 and has since been the subject of numerous studies due to its promising effects on cognition and brain health.

Why is it considered a nootropic? The term "nootropic" was coined by Dr. Corneliu E. Giurgea, the same scientist who discovered piracetam. A nootropic is defined as a substance that can improve cognitive function, particularly in areas such as memory and attention, without causing toxic side effects. Since piracetam was the first compound to display these properties, it is considered the prototype of nootropics.

Mechanism of action : The exact mechanism of action of piracetam remains the subject of debate and research. However, it is believed to act by enhancing cholinergic neurotransmission, improving neuronal membrane fluidity and modulating certain receptors, including those for the neurotransmitter glutamate. Additionally, it appears to have properties that improve blood flow and oxygen in the brain.

Benefits of Piracetam :

1. Cognitive improvement : Increases memory, concentration and mental processing speed in some individuals.
2. Neuronal protection : It has neuroprotective properties, protecting brain cells from damage and stress.
3. Improved learning : Enhances learning ability and information retention.
4. Recovery after brain injuries : It has been studied in people with traumatic brain injuries and strokes, showing promise in improving recovery.
5. Improved cerebral blood flow : Increases blood circulation in the brain, which may contribute to its nootropic effects.
6. Reducing symptoms of cognitive decline : May help relieve some symptoms in people with cognitive decline or dementia.
7. Anti-amnesia effect : May prevent or reverse certain forms of induced amnesia.
8. Synergistic effect with other nootropics : It is often combined with other nootropics to enhance their effects.
9. Safety : It has a well-established safety profile when taken at recommended doses.
10. Improved mood and anxiety : Although not its primary use, some users report a reduction in symptoms of depression and anxiety.

Absorption: For piracetam, here are the considerations regarding its absorption:

1. Water solubility : Since piracetam is soluble in water, it does not require the presence of fats to be properly absorbed. It can be taken with or without food. Although consuming it with a meal may reduce the chance of stomach upset in some people.
2. Oral route : Piracetam is commonly taken orally, either in capsule, tablet form, or as a powder dissolved in water.
3. Split doses : To maintain constant levels in the body, many users divide their daily dose of piracetam into 2 or 3 doses throughout the day. This is due to the relatively short half-life of piracetam.
4. Avoid alcohol : It is recommended to avoid alcohol while taking piracetam, as it may affect its effectiveness and enhance the effects of alcohol.

Adverse Effects: As with many compounds, although piracetam is generally very well tolerated, it may cause side effects in some people. Possible side effects include:

1. Gastrointestinal problems: This can manifest as nausea, diarrhea, or stomach upset.
2. Insomnia: Some people have reported problems sleeping when taking piracetam, especially if they take it later in the day.
3. Headache: This is one of the most common side effects, and may be the result of a cholinergic imbalance in the brain. It is often recommended to supplement with a choline source (such as citicoline or Alpha GPC) to counteract this effect.
4. Nervousness or agitation: Some users report feeling nervous or restless after taking piracetam.
5. Dizziness: This is a less common side effect, but still possible.
6. Skin Reactions: Although rare, some individuals have reported allergic skin reactions.

Contraindications:

1. Kidney conditions: People with kidney problems should be especially cautious, since piracetam is excreted through the kidneys. It is essential to adjust the dose according to kidney function or refrain from use if you have severe kidney failure.
2. Bleeding and clotting disorders: Piracetam can increase blood flow and potentially affect clotting. Those with bleeding disorders or who will undergo surgery should be cautious.
3. Drug Interaction: It is always crucial to consult with a doctor before combining piracetam with other medications, especially those that affect clotting or have effects on the central nervous system.
4. Pregnancy and breast-feeding: The safety of piracetam during pregnancy and breast-feeding has not been established, so it is generally advised to avoid its use in these circumstances.

It is important that although piracetam has shown multiple benefits and has a long history of use, consumers should be aware that their response may vary. It is always advisable to consult with a health professional before starting any supplementation, especially if there are pre-existing medical conditions or if you are taking medication.

More information about Piracetam and its dosage: https://nootropicsexpert.com/piracetam/

Study references:

[i] Genton P., Van Vleymen B. “Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.” Epileptic Disorders . 2000 Jun;2(2):99-105. ( source )

[ii] Shorvon S. “Pyrrolidone derivatives.” Lancet . 2001 Dec 1;358(9296):1885-92. ( source )

[iii] Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R., Verri WA Jr. “Analgesic activity of piracetam: effect on cytokine production and oxidative stress.” Pharmacology, Biochemistry and Behavior . 2013 Apr;105:183-92. ( source )

[iv] Bering B., Müller WE “Interaction of piracetam with several neurotransmitter receptors in the central nervous system. Relative specificity for 3H-glutamate sites.” Arzneimittelforschung . 1985;35(9):1350-2. ( source )

[v] Genton P., Van Vleymen B. “Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.” Epileptic Disorders . 2000 Jun;2(2):99-105. ( source )

[vi] Malykh AG, Sadaie MR “Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.” Drugs . 2010 Feb 12;70(3):287-312. ( source )

[vii] Purves D., Augustine GJ, Fitzpatrick D., et al., editors. “Glutamate Receptors” Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates; 2001. ( source )

[viii] Ahmed AH, Oswald RE “Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors.” Journal of Medicinal Chemistry . 2010 Mar 11;53(5):2197-203. ( source )

[ix] Stoll L., Schubert T., Müller WE “Age-related deficits of central muscarinic cholinergic receptor function in the mouse: partial restoration by chronic piracetam treatment.” Neurobiology of Aging . 1992 Jan-Feb;13(1):39-44. ( source )

[x] Cohen SA, Müller WE “Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain.” Pharmacology . 1993 Oct;47(4):217-22. ( source )

[xi] Williams JM, Guévremont D., Kennard JT, Mason-Parker SE, Tate WP, Abraham WC “Long-term regulation of N-methyl-D-aspartate receptor subunits and associated synaptic proteins following hippocampal synaptic plasticity.” Neuroscience . 2003;118(4):1003-13. ( source )

[xii] Kojiro I., Secher NH “Cerebral blood flow and metabolism during exercise” Progress in Neurobiology Volume 61, Issue 4, July 2000, Pages 397–414 ( source )

[xiii] Kessler J., Thiel A., Karbe H., Heiss WD “Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients.” Stroke . 2000 Sep;31(9):2112-6. ( source )

[xiv] Copani A., Genazzani AA, Aleppo G., Casabona G., Canonico PL, Scapagnini U., Nicoletti F. “Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid- “glutamate receptors in neuronal sensitive cultures.” Journal of Neurochemistry . 1992 Apr;58(4):1199-204. ( source )

[xv] Pepeu G., Spignoli G. “Nootropic drugs and brain cholinergic mechanisms.” Progress in Neuro-psychopharmacology and Biological Psychiatry . 1989;13 Suppl:S77-88. ( source )

[xvi] Pilch H., Müller WE “Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice.” Psychopharmacology (Berl). 1988;94(1):74-8. ( source )

[xvii] Grau M., Montero JL, Balasch J. “Effect of Piracetam on electrocorticogram and local cerebral glucose utilization in the rat.” General Pharmacology . 1987;18(2):205-11. ( source )

[xviii] Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R., Verri WA Jr. “Analgesic activity of piracetam: effect on cytokine production and oxidative stress.” Pharmacology, Biochemistry and Behavior . 2013 Apr;105:183-92. ( source )

[xix] Dimond SJ, Brouwers EM “Increase in the power of human memory in normal man through the use of drugs.” Psychopharmacology (Berl). 1976 Sep 29;49(3):307-9. ( source )

[xx] Waegemans T., Wilsher CR, Danniau A., Ferris SH, Kurz A., Winblad B. “Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.” Dementia and Geriatric Cognitive Disorders . 2002;13(4):217-24. ( source )

[xxi] Kretschmar JH, Kretschmar CH “[On the dose-effect relationship in the therapy with piracetam (author's transl)].” in German Arzneimittelforschung . 1976;26(6):1158-9. ( source )

[xxii] Stockburger C., Kurz C., Koch KA, Eckert SH, Leuner K., Müller WE “Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam.” Biochemical Social Transactions . 2013 Oct;41(5):1331-4. ( source )

[xxiii] Platel A., Jalfre M., Pawelec C., Roux S., Porsolt RD “Habituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processes.” Pharmacology, Biochemistry and Behavior . 1984 Aug;21(2):209-12. ( source )